Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial

Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial

Abstract Background SGTL2-inhibitors are a cornerstone in the treatment of heart failure, but data on patients with acute myocardial infarction (AMI) is limited. The EMMY trial was the first to show a significant reduction in NTproBNP levels as well as improved cardiac structure and function in post...

Full description

Bibliographic Details
Main Authors: Martin Benedikt, Harald Mangge, Faisal Aziz, Pero Curcic, Sabine Pailer, Markus Herrmann, Ewald Kolesnik, Norbert J. Tripolt, Peter N. Pferschy, Markus Wallner, Andreas Zirlik, Harald Sourij, Dirk von Lewinski
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Cardiovascular Diabetology
Subjects:
Empagliflozin
Myocardial infarction
Inflammation
Interleukin-6
High-sensitive c-reactive protein
Online Access:https://doi.org/10.1186/s12933-023-01904-6

Internet

https://doi.org/10.1186/s12933-023-01904-6

Similar Items